Erstes kausal wirkendes Medikament gegen Alzheimer?: Die FDA lässt Aducanumab zu

por Hager, Klaus
Publicado 2021

Alzheimer-Erkrankung – welche Substanzen befinden sich derzeit in Phase-III-Studien?

por Hager, Klaus
Publicado 2022

Teaching in Geriatrics: Is structured written feedback effective for lectures

por Pohlmann, Theresa, Hager, Klaus, Paulmann, Volker, Steffens, Sandra
Publicado 2021

Living with and dying from advanced heart failure: understanding the needs of older patients at the end of life

por Klindtworth, Katharina, Oster, Peter, Hager, Klaus, Krause, Olaf, Bleidorn, Jutta, Schneider, Nils
Publicado 2015

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease

por Hager, Klaus, Baseman, Alan S, Nye, Jeffrey S, Brashear, H Robert, Han, John, Sano, Mary, Davis, Bonnie, Richards, Henry M
Publicado 2014

Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-contro...

por Hager, Klaus, Baseman, Alan S., Nye, Jeffrey S., Brashear, H. Robert, Han, John, Sano, Mary, Davis, Bonnie, Richards, Henry M.
Publicado 2016